3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Filgrastim
9
X-Rays
7
Phantoms, Imaging
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Granulocyte Colony-Stimulating Factor
6
Temozolomide
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Cyclophosphamide
5
Busulfan
5
Stem Cell Transplantation
4
Carboplatin
4
Biopsy
4
Topotecan
3
Thiotepa
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Itraconazole
3
Ifosfamide
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
sargramostim
2
palbociclib
2
olaparib
2
liposomal amphotericin B
2
larotrectinib
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
pegylated granulocyte colony-stimulating factor
×
CNS
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled